Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis’ cash ...

The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14% from the prior estimate of $20.25 dated December 18, 2025. The price ...

Concentra Biosciences' $3/share + CVR bid for SLRN is superior to the ALMS stock-for-stock offer, presenting us with a 20% spread in favor of its bid. SLRN's remaining Phase 2 asset, Lonigutamab, has ...

A number of startups are experimenting with what a better social app could look like. For a startup called Alms, the answer is a social network that focuses on users' well-being through participation ...

As of January 29, 2025, the average one-year price target for Alumis is $30.60/share. The forecasts range from a low of $25.25 to a high of $39.90. The average price target represents an increase of ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

) has been revised to $36.28 / share. This is an increase of 79.14% from the prior estimate of $20.25 dated December 18, 2025. The price target is an average of many targets provided by analysts. The ...